Arcadia Investment Management Corp MI Acquires Shares of 870 Vericel Co. (NASDAQ:VCEL)

Arcadia Investment Management Corp MI acquired a new position in shares of Vericel Co. (NASDAQ:VCEL) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 870 shares of the biotechnology company’s stock, valued at approximately $48,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of VCEL. International Assets Investment Management LLC raised its stake in Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 322 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Vericel during the third quarter worth approximately $92,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,240 shares in the last quarter.

Insider Buying and Selling

In related news, Director Paul K. Wotton sold 2,600 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total transaction of $152,672.00. Following the completion of the sale, the director now directly owns 27,402 shares of the company’s stock, valued at $1,609,045.44. This trade represents a 8.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,100 shares of company stock valued at $1,206,072 over the last quarter. 5.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on VCEL. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Wednesday, January 15th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. Truist Financial upped their price objective on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. BTIG Research lifted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Finally, Stephens reissued an “overweight” rating and issued a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $63.14.

Vericel Stock Performance

NASDAQ VCEL opened at $52.00 on Friday. The firm’s fifty day moving average is $57.75 and its two-hundred day moving average is $51.54. Vericel Co. has a one year low of $39.12 and a one year high of $63.00. The firm has a market cap of $2.57 billion, a PE ratio of 866.81 and a beta of 1.72.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.